bluebird bio and Gritstone Oncology will collaborate to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary Edge artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors directed to those targets for use in bluebird bio’s established cell therapy platforms. bluebird bio will conduct all development, manufacturing and commercial activities. Gritstone Oncology will utilize its proprietary technology platform to enable patient selection for clinical development of such therapies. Gritstone Oncology will receive $20M in an upfront payment and an additional $10M in the form of a Series C preferred equity investment. In addition, Gritstone Oncology is eligible for significant development, regulatory and commercial milestones on any therapies, and tiered royalties on certain approved therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.